Jacobs Levy Equity Management, Inc Ultragenyx Pharmaceutical Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 303,565 shares of RARE stock, worth $8.53 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
303,565Holding current value
$8.53 Million% of portfolio
0.05%Shares
18 transactions
Others Institutions Holding RARE
# of Institutions
363Shares Held
89.2MCall Options Held
3.64MPut Options Held
2.24M-
Vanguard Group Inc Valley Forge, PA10.2MShares$287 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$158 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$111 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.89MShares$81.1 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.77MShares$77.9 Million1.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $1.97B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...